title: Atrial fibrillation and anticoagulation therapy: different race, different risk, and different management?
authors.forename: David
authors.initials: D
authors.lastname: Vivas
authors.forename: Carmen
authors.initials: C
authors.lastname: Olmos
authors.forename: Isidre
authors.initials: I
authors.lastname: Vilacosta
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D044466:Asian People; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000208:ethnology; D001777:Blood Coagulation / Q000187:drug effects*; D016903:Drug Monitoring / Q000379:methods; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D019983:Guideline Adherence; D006801:Humans; D019934:International Normalized Ratio; D007564:Japan; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000097:blood / Q000208:ethnology / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014859:Warfarin